Get started
INOVIO PHARMACEUTICALS, INCINOVIO PHARMACEUTICALS, INCINOVIO PHARMACEUTICALS, INC

INOVIO PHARMACEUTICALS, INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

INO chart


Full chart

Key facts today

HC Wainwright & Co. has maintained a 'Neutral' rating on Inovio Pharmaceuticals, Inc. (INO) and has cut the price target to $5.00 per share from a previous target of $12.00.
Analyze the impactAnalyze the impact

INO upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.27 B‬ MXN
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−88.36 MXN
Net income (FY)
‪−2.29 B‬ MXN
Revenue (FY)
‪14.13 M‬ MXN
Shares float
‪25.80 M‬
Beta (1Y)
1.82

Employees


Employees (FY)
122
Change (1Y)
−62 −33.70%
Revenue / Employee (1Y)
‪6.82 K‬ MXN
Net income / Employee (1Y)
‪−1.11 M‬ MXN

About Inovio Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Jacqueline E. Shea
Headquarters
Plymouth Meeting
Website
inovio.com
Founded
1983
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

INO news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of INO is 89.00 MXN — it has decreased by −11.64% in the past 24 hours. Watch INOVIO PHARMACEUTICALS, INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange INOVIO PHARMACEUTICALS, INC stocks are traded under the ticker INO.
INO stock has fallen by −20.61% compared to the previous week, the month change is a −20.21% fall, over the last year INOVIO PHARMACEUTICALS, INC has showed a 13.75% increase.
We've gathered analysts' opinions on INOVIO PHARMACEUTICALS, INC future price: according to them, INO price has a max estimate of 366.73 MXN and a min estimate of 101.87 MXN. Watch INO chart and read a more detailed INOVIO PHARMACEUTICALS, INC stock forecast: see what analysts think of INOVIO PHARMACEUTICALS, INC and suggest that you do with its stocks.
INO stock is 15.11% volatile and has beta coefficient of 1.82. Track INOVIO PHARMACEUTICALS, INC stock price on the chart and check out the list of the most volatile stocks — is INOVIO PHARMACEUTICALS, INC there?
Today INOVIO PHARMACEUTICALS, INC has the market capitalization of ‪2.15 B‬, it has decreased by −6.91% over the last week.
Yes, you can track INOVIO PHARMACEUTICALS, INC financials in yearly and quarterly reports right on TradingView.
INOVIO PHARMACEUTICALS, INC is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
INO earnings for the last quarter are −17.54 MXN per share, whereas the estimation was −22.66 MXN resulting in a 22.61% surprise. The estimated earnings for the next quarter are −18.54 MXN per share. See more details about INOVIO PHARMACEUTICALS, INC earnings.
INOVIO PHARMACEUTICALS, INC revenue for the last quarter amounts to 0.00 MXN, despite the estimated figure of ‪2.22 M‬ MXN. In the next quarter, revenue is expected to reach ‪1.10 M‬ MXN.
INO net income for the last quarter is ‪−495.85 M‬ MXN, while the quarter before that showed ‪−591.29 M‬ MXN of net income which accounts for 16.14% change. Track more INOVIO PHARMACEUTICALS, INC financial stats to get the full picture.
No, INO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 19, 2024, the company has 122.00 employees. See our rating of the largest employees — is INOVIO PHARMACEUTICALS, INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INOVIO PHARMACEUTICALS, INC EBITDA is ‪−2.30 B‬ MXN, and current EBITDA margin is ‪−15.83 K‬%. See more stats in INOVIO PHARMACEUTICALS, INC financial statements.
Like other stocks, INO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INOVIO PHARMACEUTICALS, INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So INOVIO PHARMACEUTICALS, INC technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating INOVIO PHARMACEUTICALS, INC stock shows the sell signal. See more of INOVIO PHARMACEUTICALS, INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.